Theralase Technologies (CVE:TLT) Trading Down 15.8% – Time to Sell?

Theralase Technologies Inc. (CVE:TLT) shares traded down 15.8% during trading on Tuesday . The company traded as low as C$0.32 and last traded at C$0.32. 116,882 shares were traded during mid-day trading, an increase of 1% from the average session volume of 115,945 shares. The stock had previously closed at C$0.38.

Theralase Technologies Price Performance

The company has a quick ratio of 3.40, a current ratio of 1.21 and a debt-to-equity ratio of 20.58. The stock has a market cap of C$76.12 million, a P/E ratio of -19.00 and a beta of 1.36. The firm has a 50 day moving average price of C$0.18 and a 200 day moving average price of C$0.18.

Theralase Technologies (CVE:TLT) last released its earnings results on Monday, August 12th. The company reported C($0.01) earnings per share for the quarter. The company had revenue of C$0.10 million for the quarter. On average, analysts forecast that Theralase Technologies Inc. will post -0.05 EPS for the current fiscal year.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.